timothy sykes logo
CMPS Soars As White House Order Supercharges Psychedelic Push Thumbnail
G Google News

CMPS Soars As White House Order Supercharges Psychedelic Push

TIM SYKES•UPDATED APR. 24, 2026, 4:38 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

COMPASS Pathways Plc stocks have been trading up by 5.03 percent following positive trial progress for its psilocybin therapy

What Traders Need To Know

  • Shares of COMPASS Pathways Plc (CMPS) jumped roughly 42%–49% on heavy volume after a U.S. executive order fast-tracked access to psychedelic treatments for serious mental illness, igniting the whole sector.
  • The company is running a rolling FDA NDA submission for its COMP360 psilocybin in treatment-resistant depression, backed by two positive Phase 3 trials and late-stage PTSD work.
  • A new U.S. grant program will fund third parties to train clinicians on delivering COMP360 after approval, signaling that COMPASS Pathways Plc is already planning for real-world deployment.
  • Collaboration with Osmind and its 1,000+ psychiatry clinics aims to build clinical and operational playbooks for COMP360 delivery if approved, supporting scale and commercialization.
  • A White House executive order, tied to at least $50M in ARPA-H funding plus priority vouchers and faster rescheduling reviews, creates a powerful policy tailwind for advanced psychedelic players such as CMPS.

Candlestick Chart

Weekly Update Apr 20 – Apr 24, 2026: On Friday, April 24, 2026 COMPASS Pathways Plc stock [NASDAQ: CMPS] is trending up by 5.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Compass Pathways (CMPS) occupies a leading position in psychedelic psychiatry with Phase 3‑validated COMP360 for TRD and an active rolling NDA, but fundamentals remain early-stage and cash-burning. Q3 2025 revenue is effectively zero, with EBITDA of -$136.5M and net loss of -$137.7M (‑$1.44 per share). ROIC at -67.6% underscores heavy value dilution risk. Balance sheet strength is the key positive: ~$186M cash, ~$45M working capital, modest debt (~$20.6M) and book value per share of ~$4 provide a 2‑3 year runway at current burn.

Technically, CMPS is in a short-term uptrend after a regulatory-news-driven spike, with the weekly series showing a rebound from 8.65 to 9.67 and higher lows each session, confirming buyers in control. Intraday 5‑minute tape shows elevated volume and repeated bids near 9.30–9.35, establishing this zone as near-term support. The dominant trend is bullish above 9.30; an actionable level is a pullback buy at 9.30–9.40 with a tight stop below 8.75 and upside toward recent momentum highs above 10.50.

Near term, CMPS is a high‑beta regulatory catalyst play, not a fundamentals-driven compounder. The White House executive order to accelerate psychedelic access, positive Phase 3 data, rolling NDA, and Osmind partnership collectively position CMPS ahead of most biotech peers on regulatory and commercialization readiness, with sentiment and volume outperformance versus healthcare and biotech benchmarks. Base case: sustained news flow drives a re‑rating toward $12–14 (implied 3–3.5x EV / peak-TRD option value) with support at 9 and resistance at 11.50.

More Breaking News

Quick Financial Overview

CMPS just saw a violent repricing after the U.S. executive order, with the stock surging between roughly 42% and 49% on heavy volume. Weekly data now show the name consolidating around the high-$8 to mid-$9 range, with recent closes near $9.67, which puts the stock modestly above book value of about $4 per share. For a development-stage biotech with a late Phase 3 asset and a rolling NDA, that kind of premium reflects high expectations but not full blue-sky pricing.

Intraday, CMPS traded a wide range from the high-$8s into the mid-$9s, with multiple reversals and a strong close near session highs. That tape says momentum buyers are active, but the frequent $0.20–$0.30 swings show two-way action and high headline sensitivity. Traders should treat this as a momentum name with sharp intraday rotations rather than a quiet swing setup.

On fundamentals, COMPASS Pathways Plc remains pre-revenue and deeply loss-making, with recent quarterly net income around -$137.7M and operating cash outflow of about -$35.1M. The balance sheet shows roughly $185.9M in cash and short-term investments and working capital near $44.9M, which helps, but the negative 67.55% one-year return on invested capital underlines that this is still a high-burn clinical story. Enterprise value sits near $1.07B, so traders are clearly pricing in meaningful upside from COMP360 approval and commercialization.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”